Published on 23 Apr 2024 on Benzinga via Yahoo Finance
FDA Approves ImmunityBio's Bladder Cancer Drug, Stock Rallies
Monday, the FDA approved ImmunityBio Inc’s (NASDAQ:IBRX) Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.
The drug is combined with the BCG vaccine, mainly used against tuberculosis and as a common treatment for some forms of bladder cancer.